90 related articles for article (PubMed ID: 23235972)
21. Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.
Chi KN; Hotte SJ; Yu EY; Tu D; Eigl BJ; Tannock I; Saad F; North S; Powers J; Gleave ME; Eisenhauer EA
J Clin Oncol; 2010 Sep; 28(27):4247-54. PubMed ID: 20733135
[TBL] [Abstract][Full Text] [Related]
22. Real-world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer.
Rulach RJ; McKay S; Neilson S; White L; Wallace J; Carruthers R; Lamb C; Cascales A; Marashi H; Glen H; Venugopal B; Sadoyze A; Sidek N; Russell JM; Alhasso A; Dodds D; Laskey J; Jones RJ; MacLeod N
BJU Int; 2018 Feb; 121(2):268-274. PubMed ID: 28940952
[TBL] [Abstract][Full Text] [Related]
23. Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial.
Manikandan R; Srirangam SJ; Pearson E; Brown SC; O'Reilly P; Collins GN
Urol Int; 2005; 75(3):217-21. PubMed ID: 16215308
[TBL] [Abstract][Full Text] [Related]
24. Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer.
Mardjuadi F; Medioni J; Kerger J; D'Hondt L; Canon JL; Duck L; Musuamba F; Oudard S; Clausse M; Moxhon A; Machiels JP
Cancer Chemother Pharmacol; 2012 Aug; 70(2):293-303. PubMed ID: 22752248
[TBL] [Abstract][Full Text] [Related]
25. High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study.
Tiffany NM; Ryan CW; Garzotto M; Wersinger EM; Beer TM
J Urol; 2005 Sep; 174(3):888-92. PubMed ID: 16093981
[TBL] [Abstract][Full Text] [Related]
26. Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC.
Pili R; Rosenthal MA; Mainwaring PN; Van Hazel G; Srinivas S; Dreicer R; Goel S; Leach J; Wong S; Clingan P
Clin Cancer Res; 2010 May; 16(10):2906-14. PubMed ID: 20460477
[TBL] [Abstract][Full Text] [Related]
27. Docetaxel plus prednisone in patients with metastatic hormone-refractory prostate cancer: an Italian clinical experience.
Cicero G; De Luca R
Eur Rev Med Pharmacol Sci; 2011 Mar; 15(3):325-31. PubMed ID: 21528780
[TBL] [Abstract][Full Text] [Related]
28. Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
Amato RJ; Hernandez-McClain J; Henary H
Am J Clin Oncol; 2008 Dec; 31(6):532-8. PubMed ID: 19060583
[TBL] [Abstract][Full Text] [Related]
29. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
30. Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model.
Li H; Raia V; Bertolini F; Price DK; Figg WD
BJU Int; 2008 Apr; 101(7):884-8. PubMed ID: 18070197
[TBL] [Abstract][Full Text] [Related]
31. Docetaxel-based chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: factors predicting response and survival.
Nayyar R; Sharma N; Gupta NP
Int J Urol; 2009 Sep; 16(9):726-31. PubMed ID: 19769656
[TBL] [Abstract][Full Text] [Related]
32. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
Soga N; Arima K; Sugimura Y
Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
[TBL] [Abstract][Full Text] [Related]
33. The preliminary results of docetaxel-prednisolone combination therapy for the Japanese patients with hormone-refractory prostate cancer.
Numata K; Miura N; Azuma K; Hashine K; Sumiyoshi Y
Hinyokika Kiyo; 2007 Feb; 53(2):93-7. PubMed ID: 17352157
[TBL] [Abstract][Full Text] [Related]
34. Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients.
Bertelli G; Heouaine A; Arena G; Botto A; Garrone O; Colantonio I; Occelli M; Fea E; Giubergia S; Merlano M
Cancer Chemother Pharmacol; 2006 Jan; 57(1):46-51. PubMed ID: 16001175
[TBL] [Abstract][Full Text] [Related]
35. Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma.
Mackler NJ; Pienta KJ; Dunn RL; Cooney KA; Redman BG; Olson KB; Fardig JE; Smith DC
Clin Genitourin Cancer; 2007 Jun; 5(5):318-22. PubMed ID: 17645828
[TBL] [Abstract][Full Text] [Related]
36. A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer.
Lin AM; Rini BI; Derynck MK; Weinberg V; Park M; Ryan CJ; Rosenberg JE; Bubley G; Small EJ
Clin Genitourin Cancer; 2007 Jun; 5(5):323-8. PubMed ID: 17645829
[TBL] [Abstract][Full Text] [Related]
37. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
Montgomery RB; Nelson PS; Lin D; Ryan CW; Garzotto M; Beer TM
Cancer; 2007 Sep; 110(5):996-1002. PubMed ID: 17639587
[TBL] [Abstract][Full Text] [Related]
38. Actual benefit of chemo-hormonal therapy in non-castrate metastatic prostate cancer.
Şendur MA; Akıncı MB; Ozdemir NY; Aksoy S; Dede DS; Ulas A; Zengin N; Yalçın B
Future Oncol; 2015; 11(8):1141-3. PubMed ID: 25832870
[No Abstract] [Full Text] [Related]
39. A randomized phase II trial comparing weekly taxotere plus prednisolone versus prednisolone alone in androgen-independent prostate cancer.
Fosså SD
Front Radiat Ther Oncol; 2008; 41():108-116. PubMed ID: 18544992
[TBL] [Abstract][Full Text] [Related]
40. Targeting metastatic prostate cancer: the search for innovative systemic therapies.
Berthold DR; Moore MJ
Oncology (Williston Park); 2006 Dec; 20(14):1787-91; discussion 1791-6. PubMed ID: 17263128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]